ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Japanese"

  • Abstract Number: 2841 • 2018 ACR/ARHP Annual Meeting

    Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup

    Mitsuhiro Takeno1, Yoshiya Tanaka2, Hajime Kono3, Shouji Sugii4, Mitsumasa Kishimoto5, Sue Cheng6, Shannon McCue6, Maria Paris6 and Hiroaki Dobashi7, 1Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 4Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 5Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 6Celgene Corporation, Summit, NJ, 7Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan

    Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in a global, phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with Behçet’s syndrome and…
  • Abstract Number: 431 • 2017 ACR/ARHP Annual Meeting

    Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis: An Interim Report of Safety Data

    Tsuneyo Mimori1, Masayoshi Harigai2, Tatsuya Atsumi3, Masataka Kuwana4, Syuji Takei5, Naoto Tamura6, Takao Fujii7, Hiroaki Matsuno8, Shigeki Momohara9, Kazuhiko Yamamoto10, Takeshi Kokubo11, Yutaka Endo11, Naonobu Sugiyama11, Tomohiro Hirose11, Yosuke Morishima11 and Noritoshi Yoshii11, 1Kyoto University, Kyoto, Japan, 2Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 3Hokkaido University, Sapporo, Japan, 4Nippon Medical School, Tokyo, Japan, 5Kagoshima University, Kagoshima, Japan, 6Juntendo University, Tokyo, Japan, 7Wakayama Medical University, Wakayama, Japan, 8Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 9Hakkeikai Inc Medical Institution, Shizuoka, Japan, 10University of Tokyo, Tokyo, Japan, 11Pfizer Japan Inc, Tokyo, Japan

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib have been shown in patients…
  • Abstract Number: 806 • 2017 ACR/ARHP Annual Meeting

    Epidemiological Study of Giant Cell Arteritis Using a Japanese Administrative Database

    Eishi Uechi and Kiyohide Fushimi, Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan

    Background/Purpose: The giant cell arteritis (GCA) management requires the administration of high-dose glucocorticoid (GC) at the introduction remission and the gradual reduction of the dosage.…
  • Abstract Number: 1165 • 2017 ACR/ARHP Annual Meeting

    Clinical Characteristics of Patients with Late-Onset Familial Mediterranean Fever in Japan

    Dai Kishida1, Masahide Yazaki1, Akinori Nakamura1, Ayako Tsuchiya-Suzuki1, Yasuhiro Shimojima2 and Yoshiki Sekijima1, 1Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, 2Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan

    Background/Purpose: Familial Mediterranean fever (FMF) is an auto-inflammatory disease characterized by recurrent episodes of fever and polyserositis. Most patients have their first febrile attack before…
  • Abstract Number: 1343 • 2017 ACR/ARHP Annual Meeting

    Gingival Bleeding and Periodontitis in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study

    Takefumi Furuya1, Eisuke Inoue2, Shigeru Maeda3, Eiichi Tanaka1, Katsunori Ikari1, Ayako Nakajima1, Atsuo Taniguchi1 and Hisashi Yamanaka1, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, 3Department of Dental Anesthesiology, Okayama University Hospital, Okayama, Japan

    Background/Purpose: Oral health is an important issue for patients with rheumatoid arthritis (RA) because periodontitis is a potential risk factor for RA and RA patients…
  • Abstract Number: 2588 • 2017 ACR/ARHP Annual Meeting

    Early Exposure to Hydroxychloroquine Predicts Good Renal Response in Japanese Patients with Lupus Nephritis Class III or IV

    Tomofumi Kiyokawa1, Hironari Hanaoka2, Harunobu Iida1, Yukiko Takakuwa1 and Kimito Kawahata1, 1Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 2Division of Rheumatology and Allergology, Department of Internal Medicine,, St. Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: The guideline or recommendation for lupus nephritis (LN) has been recently established by both ACR and EULAR, and hydroxychloriquine (HCQ) is recommended for all…
  • Abstract Number: 608 • 2016 ACR/ARHP Annual Meeting

    Initial Intensive Therapy of Adalimumab and Methotrexate Is Associated with Long-Term Structural Remission and Low Disease Activity after Adalimumab Discontinuation Is Maintained up to 3 Years in Japanese Patients: Hopeful-3 Study

    Yoshiya Tanaka1, Hisashi Yamanaka2, Naoki Ishiguro3, Nobuyuki Miyasaka4, Katsuyoshi Kawana5, Naoki Agata5 and Tsutomu Takeuchi6, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Tokyo Women's Medical University, Tokyo, Japan, 3Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Japan, 4Tokyo Medical and Dental University, Tokyo, Japan, 5Abbvie GK, Tokyo, Japan, 6Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose:   Methods:   Of 172 patients enrolled, 135 (ADA continuation, n=61; ADA discontinuation, n=74) with DAS28–CRP at both week 52 (start of HOPEFUL-2) and week 208…
  • Abstract Number: 609 • 2016 ACR/ARHP Annual Meeting

    Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the Anouveau Study (Clinicaltrial.gov: NCT01346488)

    Yoshiya Tanaka1, Kiyotaka Yamazaki2, Ryo Nakajima2, Shuichi Komatsu3, Naoki Agata4, Ataru Igarashi5, Toshiro Tango6 and Tsutomu Takeuchi7, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Post Marketing Study Group, Medical, AbbVie GK, Tokyo, Japan, 3Scientific Project Manager Group, Medical, AbbVie GK, Tokyo, Japan, 4Medical Communication, Medical, AbbVie GK, Tokyo, Japan, 5Department of Drug Policy & Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan, 6Center for Medical Statistics, Tokyo, Japan, 7Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Patients with Rheumatoid Arthritis (RA) experience loss of productivity such as missing their work and lowering their performance incurred by impaired physical functioning. Treatment…
  • Abstract Number: 1598 • 2016 ACR/ARHP Annual Meeting

    Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes

    Mark C. Genovese1, Patrick Durez2, Roy Fleischmann3, Yoshiya Tanaka4, Daniel E. Furst5, Hisashi Yamanaka6, Igor Vasyutin7, Thangavel Kaviarasu8, Elena Korneva7, Dmitry Koloda7 and Tsutomu Takeuchi9, 1Stanford University Medical Center, Palo Alto, CA, 2Department of Rheumatology, Université Catholique de Louvain, Brussels, Belgium, 3Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 4The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 5David Geffen School of Medicine at UCLA, Los Angeles, CA, 6Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 7R-Pharm CJSC, Moscow, Russian Federation, 8Quintiles Inc, Mumbai, India, 9School of Medicine, Keio University, Tokyo, Japan

    Background/Purpose: Rheumatoid arthritis (RA) has a high patient (pt) burden with significant impact on health-related quality of life. We report the effect of treatment with…
  • Abstract Number: 331 • 2016 ACR/ARHP Annual Meeting

    Biologic Disease-Modifying Anti-Rheumatic Drug Use and the Risk of Non-Vertebral Osteoporotic Fractures in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study

    Takefumi Furuya1, Eisuke Inoue1,2, Masanori Nakayama1, Eiichi Tanaka1, Katsunori Ikari1, Ayako Nakajima3, Atsuo Taniguchi1 and Hisashi Yamanaka1, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Center for Clinical Research and Development, National Center for Child Health and Development, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose:   Previous U.S. and Canadian studies [1-3] have suggested that no significant associations exist between use of biologic disease-modifying anti-rheumatic drugs (DMARDs) and risk of…
  • Abstract Number: 344 • 2015 ACR/ARHP Annual Meeting

    Results of a Phase 2 Clinical Trial to Evaluate the Effects of Romosozumab in Japanese Women with Postmenopausal Osteoporosis

    H Ishibashi1, DB Crittenden2, A Miyauchi3, C Libanati4, J Maddox2, L Chen2 and A Grauer2, 1Ina Hospital, Saitama, Japan, 2Amgen Inc., Thousand Oaks, CA, 3Miyauchi Medical Center, Osaka, Japan, 4UCB Pharma, Brussels, Belgium

     Background/Purpose: Romosozumab is a sclerostin inhibitor that rapidly increases bone mineral density (BMD) through a dual effect on bone, causing increased bone formation and decreased…
  • Abstract Number: 349 • 2015 ACR/ARHP Annual Meeting

    Comparison Between the American Recommendations and the Japanese Guidelines for Glucocorticoid-Induced Osteoporosis in Japanese Patients with Rheumatoid Arthritis

    Takefumi Furuya, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) updated their guidelines for the management and treatment of glucocorticoid-induced osteoporosis (GIO) and…
  • Abstract Number: 384 • 2015 ACR/ARHP Annual Meeting

    Dental Treatments, Tooth Extraction, and Osteonecrosis at Jaw in Japanese Patients with Rheumatoid Arthritis; Results from the IORRA Cohort Study

    Takefumi Furuya, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: Oral health is an important issue for the patients with rheumatoid arthritis (RA) because many RA patients were treated with bisphosphonates and bisphosphate use…
  • Abstract Number: 2470 • 2014 ACR/ARHP Annual Meeting

    Treatment Strategy for Maximizating the Effect of Adalimumab in Japanese Patients with Rheumatoid Arthritis : Retrospective Analyses of Data Collected from the Patient Treated with Adalimumab in Routine Clinical Practice in Hamamatsu Area

    Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan

    Background/Purpose: Adalimumab (ADA) showed highly efficacious in rheumatoid arthritis (RA) in the clinical trials, although there is little evidence in daily clinical practice.The clinical usefulness…
  • Abstract Number: 2418 • 2014 ACR/ARHP Annual Meeting

    Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data

    Naonobu Sugiyama M.D., Ph.D1, Tatsunori Murata, M.S.2, Yosuke Morishima3, Yuri Fukuma4, Yoshiyuki Shibasaki4 and Lisa Marshall5, 1Medical Affairs, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, 2Health Economics Research Group, CRECON Research and Consulting Inc., Tokyo, Japan, 3RA & Inflammation Area Medical Affairs Department, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, 4Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, 5Inflammation Immunology Disease Group, Pfizer Inc. Inflammation Immunology Disease Group, Collegeville, PA

    Background/Purpose Biologics such as etanercept (ETN), adalimumab (ADA), infliximab (IFX) and tocilizumab (TCZ) have led dramatic improvement in the treatment of rheumatoid arthritis (RA), but…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology